**MONOGRAPH**

**Griseofulvin Monograph - Paediatric**

**Scope (Staff):** Medical, Pharmacy, Nursing,

**Scope (Area):** All Clinical Areas – Perth Children’s Hospital

---

**Child Safe Organisation Statement of Commitment**

CAHS commits to being a child safe organisation by applying the National Principles for Child Safe Organisations. This is a commitment to a strong culture supported by robust policies and procedures to reduce the likelihood of harm to children and young people.

---

**DISCLAIMER**

This document should be read in conjunction with this DISCLAIMER

---

**QUICKLINKS**

- Dosage/Dosage Adjustments
- Administration
- Compatibility
- Monitoring

---

**DRUG CLASS**

Antifungal

---

**INDICATIONS AND RESTRICTIONS**

Griseofulvin is used in the treatment of dermatophyte infections of the skin that:

- Are widespread and/or hyperkeratotic
- Involve sites where topical treatment is not recommended (e.g. infection involving the scalp, palms or soles) or
- Have not responded to topical therapy.\(^{(2, 3)}\)

An accurate mycological diagnosis is desirable prior to commencing griseofulvin treatment as its activity is restricted to dermatophyte infections. Griseofulvin has no activity against yeasts such as *Candida* species or *Malassezia furfur*.\(^{(1, 4)}\)

**Oral: Unrestricted (green) antifungal**

This is not a restricted agent. Follow standard ChAMP guidelines where appropriate.

---

**CONTRAINdications**

- Hypersensitivity to griseofulvin or any component of the formulation.
- Griseofulvin is category D and is contraindicated in pregnancy and women intending to become pregnant within one month of cessation of griseofulvin treatment.\(^{(2, 5)}\) The manufacturer advises men not to father children during and for 6 months after treatment as griseofulvin may affect sperm.\(^{(2)}\)
- Griseofulvin is contraindicated in patients with Lupus erythematosus.\(^{(1, 5-7)}\)
- Griseofulvin is contraindicated in severe liver disease as it may cause liver function to worsen.\(^{(5)}\)
- Griseofulvin is contraindicated in patients with acute porphyrias due to the risk of inducing a porphyric crisis.\(^{(5-7)}\)

**PRECAUTIONS**

- Patients should avoid exposure to sunlight due to the risk of photosensitivity reactions. Patients should be instructed to wear protective clothing, a hat, sunglasses and sunscreen (physical sunscreen is preferred to chemical sunscreen) while taking griseofulvin.\(^{(1, 5)}\)
- Griseofulvin reduces the efficacy of the oral contraceptive pill, sexually active adolescent females should use effective non-hormonal contraception whilst taking griseofulvin and for at least 4 weeks after ceasing therapy.\(^{(1)}\)

**FORMULATIONS**

Listed below are products available at PCH, other formulations may be available, check with pharmacy if required:
- 125mg and 500mg oral tablets
  Imprest location: Formulary One

**DOSAGE & DOSAGE ADJUSTMENTS**

**Neonates:** Not routinely used in neonates (less than 30 days of age), contact Infectious Diseases or Clinical Microbiology for advice.

**Children:**

- **1 month to 12 years:** 10-20mg/kg (to a maximum of 1 gram) once daily. If using the higher dose, reduce dose when clinical improvement occurs.\(^{(2, 4, 6)}\)
- **>12 years to 18 years:** 500mg daily. Up to 1 gram daily can be used for severe infections; reduce dose once response occurs.\(^{(2, 4, 6)}\)

Use the higher dose in patients being treated for tinea capitis caused by *Trichophyton tonsurans*, or alternatively, use terbinafine.\(^{(6)}\)

Duration of therapy is dependent on the site of the infection.
- Tinea capitis: 4 to 6 weeks
- Tinea corporis: 2 to 4 weeks
- Tinea unguium (onychomycosis): at least 4 months for fingernails and at least 6 months for toes nails.\(^{(5)}\)

**Renal impairment:**

- Dosage reduction is generally not required in cases of significant renal impairment. Contact Pharmacy for advice.\(^{(5, 7)}\)

**Hepatic impairment:**

- Although no specific dose adjustments are required, griseofulvin is contraindicated in severe liver disease as it undergoes hepatic metabolism and may worsen liver function.\(^{(5-7)}\)
ADMINISTRATION

- Griseofulvin should be administered with a high fat meal (for example peanut butter or ice-cream) or milk to increase absorption and to avoid stomach upset.\(^{(1, 5, 7)}\)

COMPATIBILITY

Not applicable

MONITORING

- Renal, hepatic and haematological function should be monitored periodically if treatment course is 8 weeks or longer.\(^{(1, 2, 5, 7)}\)

ADVERSE EFFECTS

**Common:** headache, nausea, diarrhoea, anorexia.\(^{(1, 6)}\)

**Infrequent:** photosensitivity, urticaria, rash, blurred vision, confusion, fatigue, dizziness, taste disturbance, insomnia, irritability, dyspepsia.\(^{(1, 8)}\)

**Rare:** toxic epidermal necrolysis, precipitation or exacerbation of lupus erythematosus, vomiting, abdominal pain, severe diarrhoea, menstrual irregularities, leucopenia, neutropenia, hypersensitivity (e.g. serum sickness like reaction), hepatotoxicity.\(^{(1, 6)}\)

STORAGE

- Store tablets below 30°C\(^{(2)}\)

INTERACTIONS

This medication may interact with other medications; consult PCH approved references (e.g. Clinical Pharmacology), a clinical pharmacist or PCH Medicines Information Service on extension 63546 for more information.

**Please note: The information contained in this guideline is to assist with the preparation and administration of griseofulvin. Any variations to the doses recommended should be clarified with the prescriber prior to administration**

Related CAHS internal policies, procedures and guidelines

- Antimicrobial Stewardship Policy
- ChAMP Empiric Guidelines and Monographs
- KEMH Neonatal Medication Protocols
Griseofulvin Monograph - Paediatric

References


This document can be made available in alternative formats on request for a person with a disability.

File Path: W:\Paediatrics\PMH\ChAMP\Monographs\FINALISED\00 Current version 00
Document Owner: Head of Department – Infectious Diseases
Reviewer / Team: Children’s Antimicrobial Management Program Pharmacist
Date First Issued: July 2018
Last Reviewed: May 2021
Amendment Dates: March 2021
Next Review Date: May 2024
Approved by: Drugs and Therapeutics Committee
Date: June 2021
Endorsed by: Chair, Drugs and Therapeutics Committee
Date: June 2021
Standards Applicable:
- NSQHS Standards:
- NSMHS: N/A
- Child Safe Standards: N/A

Printed or personally saved electronic copies of this document are considered uncontrolled.